GeneDx price target raised to $45 from $35 at BTIG

BTIG analyst Mark Massaro raised the firm’s price target on GeneDx to $45 from $35 and keeps a Buy rating on the shares following “another beat and raise” quarter. GeneDx management team has done one of the best turnarounds seen in the space in the last decade, and while the company reiterated its goal to achieve profitability in 2025, this is a conservative outlook as the company will likely get there sooner than expected, the analyst tells investors in a research note.